|
1
|
Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial.
|
J Am Coll Cardiol
|
2010
|
2.43
|
|
2
|
High washout rate of iodine-123-metaiodobenzylguanidine imaging predicts the outcome of catheter ablation of atrial fibrillation.
|
J Cardiovasc Electrophysiol
|
2011
|
1.04
|
|
3
|
Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation.
|
Am J Cardiol
|
2009
|
0.95
|
|
4
|
Prevalence and characteristics of asymptomatic excessive transmural injury after radiofrequency catheter ablation of atrial fibrillation.
|
Heart Rhythm
|
2011
|
0.94
|
|
5
|
Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism.
|
Br J Clin Pharmacol
|
2009
|
0.89
|
|
6
|
Feasibility of targeting catheter ablation to the markedly low-voltage area surrounding infarct scars in patients with post-infarction ventricular tachycardia.
|
Circ J
|
2008
|
0.87
|
|
7
|
Electrocardiographic determinants of the polymorphic QRS morphology in idiopathic right ventricular outflow tract tachycardia.
|
J Cardiovasc Electrophysiol
|
2011
|
0.86
|
|
8
|
Ventricular fibrillation during anesthesia in association with J waves in the left precordial leads in a child with coarctation of the aorta.
|
J Electrocardiol
|
2003
|
0.84
|
|
9
|
Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.
|
Eur J Clin Pharmacol
|
2006
|
0.81
|
|
10
|
Increased plasma levels of big-endothelin-2 and big-endothelin-3 in patients with end-stage renal disease.
|
Life Sci
|
2012
|
0.80
|
|
11
|
Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography.
|
J Pharm Biomed Anal
|
2004
|
0.78
|
|
12
|
Sleep apnea and ventricular arrhythmias: Clinical outcome, electrophysiologic characteristics, and follow-up after catheter ablation.
|
J Cardiol
|
2009
|
0.78
|
|
13
|
Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia.
|
Eur J Clin Pharmacol
|
2007
|
0.78
|
|
14
|
Assessment of serum flecainide trough levels in patients with tachyarrhythmia.
|
J Pharm Pharmacol
|
2005
|
0.78
|
|
15
|
Noninvasive recording of his potential using magnetocardiograms.
|
Circ J
|
2003
|
0.77
|
|
16
|
CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
|
Pharmacogenet Genomics
|
2012
|
0.76
|
|
17
|
A novel mutation associated with Jervell and Lange-Nielsen syndrome in a Japanese family.
|
Circ J
|
2008
|
0.76
|
|
18
|
Intracardiac lead fracture in an implantable cardioverter-defibrillator.
|
Int Heart J
|
2005
|
0.75
|
|
19
|
SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients.
|
Pharmacogenet Genomics
|
2013
|
0.75
|
|
20
|
Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity.
|
Biomed Chromatogr
|
2014
|
0.75
|
|
21
|
Effects of linear ablation at the isthmus between the tricuspid annulus and inferior vena cava for atrial flutter on autonomic nervous activity: analysis of heart rate variability.
|
Circ J
|
2002
|
0.75
|
|
22
|
β1-Adrenergic receptor Arg389Gly polymorphism affects the antiarrhythmic efficacy of flecainide in patients with coadministration of β-blockers.
|
Pharmacogenet Genomics
|
2016
|
0.75
|
|
23
|
Noninvasive diagnosis of partial atrial standstill using magnetocardiograms.
|
Circ J
|
2002
|
0.75
|
|
24
|
Endothelin-1-induced cardiomyocyte hypertrophy is partly regulated by transcription factor II-F interacting C-terminal domain phosphatase of RNA polymerase II.
|
Life Sci
|
2012
|
0.75
|
|
25
|
Liquid chromatographic determination of unbound flecainide in therapeutic drug monitoring.
|
J Pharm Biomed Anal
|
2003
|
0.75
|
|
26
|
High performance liquid chromatography for routine monitoring of serum flecainide.
|
J Pharm Biomed Anal
|
2002
|
0.75
|